Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Combinations of the Presence or Absence of Cerebral Microbleeds and Advanced White Matter Hyperintensity as Predictors of Subsequent Stroke Types
AJNR 27:830-835, Naka,H.,et al, 2006
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder
Brain 129:3150-3164, Jellema, K., et al, 2006
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke
Stroke 36:1115-1119, Marini,C.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Silent Ischemia in Minor Stroke and TIA Patients Identified on MR Imaging
Neurol 65:513-517, Coutts,S.B.,et al, 2005
High Titers of CA-125 May Be Associated weith Recurrent Ischemic Strokes in Patients with Cancer
Neurol 64:1944-1945, Jovin,T.G.,et al, 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Anti-a4 Integrin Therapy for Multiple Sclerosis
Neurol 64:1336-1342, Rice,G.P.A.,et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Recurrent Stroke Associated with Cannabis Use
JNNP 76:435-437, Mateo,I.,et al, 2005
Intracranial Haemorrhages in French Haemophilia Patients (1991-2001): Clinical Presentation, Management and Prognosis Factors for Death
Haemophilia 11:452-458, Stieltjes,N.,et al, 2005
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Lowering Homocysteine in Patients with Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death
JAMA 291:565-575,621, Toole,J.F.,et al, 2004
Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients with Ischemic Stroke
JAMA 291:576-584, The APASS Investigators, 2004
Practice Parameter: Recurrent Stroke with Patent Foramen Ovale and Atrial Septal Aneurysm
Neurol 62:1042-1050, Messe,S.R.,et al, 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Hemorrhage Burden Predicts Recurrent Intracerebral Hemorrhage After Lobar Hemorrhage
Stroke 35:1415-1420, Greenberg,S.M.,et al, 2004
Clinical and MRI Outcome after Autologous Hematoipoietic Stem Cell Transplantation in MS
Neurol 62:282-284,168, Saiz,A.,et al, 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004
Early Risk of Recurrence by Subtype of Ischemic Stroke in Population-Based Incidence Studies
Neurol 62:569-573, Lovett,J.K.,et al, 2004
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Peripheral Neuropathy
Lancet 363:2151-2161, England,J.D. &Asbury,A.K., 2004
Poststroke Neurological Improvement Within 7 Days Is Associated with Subsequent Deterioration
Stroke 35:2165, Aslanyan,S.,et al, 2004
Multiple Acute Cerebral Infarcts on Diffusion-Weighted Imaging and Risk of Recurrent Stroke
Neurol 63:1317-1319, Wen,H.M.,et al, 2004
The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003
Frequency and Mechanisms of Stroke Recurrence After Cryptogenic Stroke
Ann Neurol 54:227-234, Bang,O.Y.,et al, 2003
Occurrence of Amyotrophic Lateral Sclerosis Among Gulf War Veterans
Neurol 61:742-749, Horner,R.D.,et al, 2003
Excess Incidence of ALS in Young Gulf War Veterans
Neurol 61:750-756, Haleyl,R.W., 2003
Relationship Between Blood Pressure and Stroke Risk in Patients with Symptomatic Carotid Occlusive Disease
Stroke 34:2583-2592, Rothwell,P.M.,et al, 2003
Constipation in Neurological Diseases
JNNP 74:13-19, Winge,K.,et al, 2003
Poor Outcome After First-Ever Stroke
Stroke 34:122-126, Appelros,P.,et al, 2003
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Early Ischemic Lesion Recurrence Within a Week After Acute Ischemic Stroke
Ann Neurol 54:66-74, Kang,D.,et al, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Immunization and MS
Neurol 59:1837-1843, Rutschmann,O.T.,et al, 2002
Prospective Assessment of Risk Factors for Recurrent Stroke During Childhood--A 5-year Follow-up Study
Lancet 360:1540-1545,1526, Strater,R.,et al, 2002
Tourette's Syndrome
Lancet 360:1577-1586, Leckman,J.F., 2002
Posterior Circulation Stroke in Childhood
Neurol 59:1552-1556, Ganesan,V.,et al, 2002
Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002
Sudden Coma From Acute Bilateral Internal Carotid Artery Territory Infarction
Neurol 58:1846-1849, Kwon,S.U.,et al, 2002